https://www.selleckchem.com/products/tepp-46.html
2±24.7min vs 19.7±21.7min; p=0.03), and decreased the obstructive apnea index (OAI) (0 vs 8.7±18.8; p=0.01). Lower mean HR (66.6±4.1 bpm vs 70.6±5.9 bpm; p=0.03) and lower maximum HR (84.1±7.3 bpm vs 91.6±7.8 bpm; p=0.03) were observed in PSG with NIV. The use of NIV in patients with moderate to severe stable COPD while they were sleeping increased REM sleep time and decreased sleep onset latency, the number of obstructive respiratory events, and the mean and maximum HR. The use of NIV in patients with moderate to severe stable COPD whi
Like
Comment
Share
